That's the central question Ryan's venture poses. She didn't invent commerce, quality control, or trait selection in human reproduction. Those trends are rampant in the egg and sperm markets. All she did was extend them across the line of conception. Does that line matter?
If it does, you'd better figure out how to square that with your views on abortion and stem-cell research. But if it doesn't, you'd better figure out where to draw the next line. Because the logic of what Ryan is offering—more control, more customization, higher quality, fewer hassles, lower cost, and lower risk—won't end here.
Tuesday, January 16, 2007
"Does that line matter?"
William Saletan discusses Abraham Center of Life's foray into creating made to order human embryos.